Domperidone

Domperidone is a dopamine antagonist that does not readily enter the central nervous system. Given parenterally or orally it increases gastric emptying of liquids and increases lower oesophageal sphincter pressure in healthy subjects. The antiemetic and pharmacodynamic profile of domperidone is similar to that of metoclopramide, although domperidone has a lower propensity to cause extrapyramidal side effects. Domperidone effectively alleviates symptoms of chronic postprandial dyspepsia and nausea and vomiting due to a wide variety of underlying causes and in some studies has been superior to metoclopramide. Vomiting associated with the administration of moderately emetic cytotoxic drugs is controlled in the majority of patients. Alleviation of the dose-limiting peripheral side effects (nausea and vomiting) of the anti-Parkinsonian drugs bromocriptine and levodopa, enables a higher optimum dose, with consequent improvement in Parkinsonian symptoms. Domperidone does not aggravate the extrapyramidal side effects of neuroleptic drugs. Control of cytotoxic-induced, and postprandial nausea and vomiting in children has been achieved with domperidone without evidence of extrapyramidal side effects. Indeed, side effects have seldom occurred with therapeutic doses of domperidone.

[1]  L. Rutgeerts,et al.  Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying. , 1979, Postgraduate medical journal.

[2]  G. Molinatti,et al.  Increased thyrotrophin and prolactin secretion induced by domperidone in hypothyroid subjects. , 1981, Acta endocrinologica.

[3]  J. Sowers,et al.  Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man. , 1982, The Journal of clinical endocrinology and metabolism.

[4]  J. Grimes,et al.  Adverse neurologic effects of metoclopramide. , 1982, Canadian Medical Association journal.

[5]  J. Valenzuela,et al.  The effect of variations in intragastric pressure and gastric emptying of a saline meal in humans. , 1982, Scandinavian journal of gastroenterology.

[6]  K. Haarmann,et al.  A double-blind study of domperidone in the symptomatic treatment of chronic post-prandial upper gastrointestinal distress. , 1979, Postgraduate medical journal.

[7]  Y. Agid,et al.  Bromocriptine and domperidone in the treatment of Parkinson disease , 1981, Neurology.

[8]  A. Broekaert.  Effect of domperidone on gastric emptying and secretion. , 1979, Postgraduate medical journal.

[9]  J. Brock‐Utne.  Domperidone Antagonizes the Relaxant Effect of Atropine on the Lower Esophageal Sphincter , 1980, Anesthesia and analgesia.

[10]  E. Kessler,et al.  The effect of intravenous domperidone on the resting lower oesophageal sphincter pressure in dogs and baboons. , 1979, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[11]  D. Cook,et al.  DOMPERIDONE: A NOVEL AGENT FOR THE INVESTIGATION OF ANTERIOR PITUITARY FUNCTION AND CONTROL IN MAN , 1980, Clinical endocrinology.

[12]  A. Stockman,et al.  Postoperative vomiting treated with domperidone. A double-blind comparison with metoclopramide and a placebo. , 1980, Acta anaesthesiologica Belgica.

[13]  I. Swann,et al.  Domperidone or metoclopramide in preventing chemotherapeutically induced nausea and vomiting. , 1979, British medical journal.

[14]  J. M. Nueten.  Is dopamine an inhibitory modulator of gastric motility , 1980 .

[15]  塩路 武徳.  Augmentation of puerperal lactation by oral administration of sulpiride , 1982 .

[16]  C. Marsden,et al.  EXTRAPYRAMIDAL SIDE-EFFECTS OF METOCLOPRAMIDE , 1978, The Lancet.

[17]  L. Rutgeerts,et al.  Oral Domperidone in Chronic Postprandial Dyspepsia , 1979 .

[18]  M. Baudry,et al.  Characterization of 3H-domperidone binding on striatal dopamine receptors. , 1978, Life sciences.

[19]  R. Roth,et al.  Brain contribution to the haloperidol-induced increase in plasma homovanillic acid. , 1981, European journal of pharmacology.

[20]  A. Genazzani,et al.  Tests of prolactin secretion in the diagnosis of hyperprolactinemic states: nomifensine and domperidone. , 1981, Fertility and sterility.

[21]  J. Leysen,et al.  Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. , 1979, Biochemical pharmacology.

[22]  R. Falk,et al.  Reduction in vulnerability to ventricular fibrillation by bromocriptine, a dopamine agonist. , 1981, Cardiovascular research.

[23]  C. Niemegeers,et al.  The antiemetic effects of domperidone, a novel potent gastrokinetic. , 1980, Archives internationales de pharmacodynamie et de therapie.

[24]  J. Guignard,et al.  EXTRAPYRAMIDAL REACTIONS DUE TO DOMPERIDONE , 1980, The Lancet.

[25]  M. Scanlon,et al.  EVIDENCE FOR DOPAMINERGIC CONTROL OF THYROTROPHIN SECRETION IN MAN , 1977, The Lancet.

[26]  J. Leysen,et al.  71 – DOMPERIDONE, A NOVEL GASTROKINETIC AND ANTI-NAUSEANT DRUG, INTERACTS SELECTIVELY WITH DOPAMINE RECEPTORS , 1978 .

[27]  D. Cocchi,et al.  Prolactin-releasing effect of a novel anti-dopaminergic drug, domperidone, in the rat. , 1980, Neuroendocrinology.

[28]  B. Cox,et al.  The dopamine receptor antagonist domperidone is also a competitive antagonist at α1‐adrenoceptors , 1980, The Journal of pharmacy and pharmacology.

[29]  B. Costall,et al.  Catecholamine‐induced relaxation and contraction of the lower oesophageal and pyloric sphincters of guinea‐pig stomach: modification by domperidone , 1982, The Journal of pharmacy and pharmacology.

[30]  P. Janssen,et al.  Is dopamine an endogenous inhibitor of gastric emptying , 1978 .

[31]  E. Van de Velde,et al.  Effects of intravenous and oral domperidone on the motor function of the stomach and small intestine. , 1979, Postgraduate medical journal.

[32]  G. Goulis,et al.  Double-Blind Evaluation of Domperidone in Acute Vomiting and Dyspeptic Disorders , 1981, The Journal of international medical research.

[33]  R. W. Ball,et al.  Prevention of postoperative nausea and vomiting by domperidone: A double-blind randomized study using domperidone, metoclopramide and a placebo. , 1979, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[34]  G. Brown,et al.  ENDOCRINE EFFECTS OF DOMPERIDONE: A PERIPHERAL DOPAMINE BLOCKING AGENT , 1981, Clinical endocrinology.

[35]  D. Schlich,et al.  A double-blind crossover trial of domperidone in chronic postprandial dyspepsia. , 1979, Postgraduate medical journal.

[36]  A. Goldhirsch,et al.  SUDDEN DEATH IN CANCER PATIENT ON HIGH-DOSE DOMPERIDONE , 1982, The Lancet.

[37]  Y. Agid,et al.  [Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)]. , 1981, Revue neurologique.

[38]  D. Cocchi,et al.  A role for dopamine in growth hormone regulation in the dog. , 1981, Endocrinology.

[39]  J. Brock‐Utne,et al.  Effect of domperidone on lower esophageal sphincter tone in late pregnancy. , 1980, Anesthesiology.

[40]  L. Lecron,et al.  Domperidone in the prevention of post-operative nausea and vomiting. , 1979, Postgraduate medical journal.

[41]  G. Molinatti,et al.  Impaired prolactin responsiveness to dopamine antagonists in acromegaly. , 1982, Metabolism: clinical and experimental.

[42]  R. Fragen,et al.  A new benzimidazole antiemetic, domperidone, for the treatment of postoperative nausea and vomiting. , 1978, Anesthesiology.

[43]  R. Fisher,et al.  Scintigraphic evaluation of gastric emptying. , 1982, Seminars in nuclear medicine.

[44]  R. Milo.  Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome. , 1980, Current medical research and opinion.

[45]  W. Wiersinga,et al.  PLASMA PROLACTIN LEVELS AFTER ACUTE AND SUBCHRONIC ORAL ADMINISTRATION OF DOMPERIDONE AND OF METOCLOPRAMIDE: A CROSS‐OVER STUDY IN HEALTHY VOLUNTEERS , 1980, Clinical endocrinology.

[46]  T. Whittingham,et al.  The effects of domperidone on gastric emptying of liquid in man. , 1982, British journal of clinical pharmacology.

[47]  L. Ameryckx,et al.  Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation. A comparison with metoclopramide. , 1979, Postgraduate medical journal.

[48]  P. Miskovitz,et al.  Clinical evaluation of domperidone in the treatment of chronic postprandial idiopathic upper gastrointestinal distress. , 1981, The American journal of gastroenterology.

[49]  G. Gessa,et al.  THERAPEUTIC EFFICACY OF APOMORPHINE COMBINED WITH AN EXTRACEREBRAL INHIBITOR OF DOPAMINE RECEPTORS IN PARKINSON'S DISEASE , 1979, The Lancet.

[50]  G. Molinatti,et al.  INCREASED THYROTROPHIN SECRETION INDUCED BY SULPIRIDE IN MAN , 1978, Clinical endocrinology.

[51]  K. Korttila,et al.  Comparison of Domperidone, Droperidol, and Metoclopramide in the Prevention and Treatment of Nausea and Vomiting after Balanced General Anesthesia , 1979, Anesthesia and analgesia.

[52]  H. Burger,et al.  INCREASED PROLACTIN AND THYROTROPHIN SECRETION FOLLOWING ORAL METOCLOPRAMIDE: DOSE‐RESPONSE RELATIONSHIPS , 1977, Clinical endocrinology.

[53]  P. Laduron,et al.  Inhibition of dopamine receptors in the stomach: an explanation of the gastrokinetic properties of domperidone. , 1978, Life sciences.

[54]  H. Bohnet,et al.  Domperidone stimulated prolactin secretion in normal male and female volunteers. , 1981, Endokrinologie.

[55]  K. Shuto,et al.  Antagonism of KW-5338 (domperidone) against emesis and depression of intestinal motility induced by L-DOPA. , 1980, Journal of pharmacobio-dynamics.

[56]  C. Invitti,et al.  Effect of gamma-aminobutyric acid on growth hormone and prolactin secretion in man: influence of pimozide and domperidone. , 1980, The Journal of clinical endocrinology and metabolism.

[57]  B. Bron,et al.  Domperidone: a drug with powerful action on the lower esophageal sphincter pressure. , 1980, Digestion.

[58]  O. Ylikorkala,et al.  A DOSE RESPONSE RELATION BETWEEN IMPROVED LACTATION AND METOCLOPRAMIDE , 1981, The Lancet.

[59]  H. Toyoshima,et al.  Effects of domperidone on serum prolactin levels in human beings. , 1980, Endocrinologia japonica.

[60]  S. Whitehead,et al.  In-vivo and in-vitro effects of domperidone on the release of prolactin and LH in male and female rats. , 1982, Journal of reproduction and fertility.

[61]  E. Heck,et al.  A double-blind comparison of domperidone and metoclopramide suppositories in the treatment of nausea and vomiting in children. , 1979, Postgraduate medical journal.

[62]  J. Hamers.  Cytostatic therapy-induced vomiting inhibited by domperidone. A double-blind cross-over study. , 1978, Biomedicine / [publiee pour l'A.A.I.C.I.G.].

[63]  J. Schuurkes,et al.  Is dopamine an inhibitory modulator of gastrointestinal motility? , 1981, Scandinavian Journal of Gastroenterology, Supplement.

[64]  D. Cocchi,et al.  Prolactin-releasing effect of domperidone in normoprolactinemic and hyperprolactinemic subjects. , 1980, Neuroendocrinology.

[65]  G. Delitala,et al.  Domperidone, an extracerebral inhibitor of dopamine receptors, stimulates thyrotropin and prolactin release in man. , 1980, The Journal of clinical endocrinology and metabolism.

[66]  H. Anthoni,et al.  Domperidone in the Treatment of Dyspepsia: A Double-Blind Placebo-Controlled Study , 1979, The Journal of international medical research.

[67]  E. Uberti,et al.  Effect of domperidone on prolactin secretion in healthy subjects. , 1980, Panminerva Medica (Testo stampato).

[68]  A. Johnson.  Flatulent dyspepsia. , 1973, Postgraduate medical journal.

[69]  J. Helmers,et al.  Domperidone (R 33 812) as an antiemetic in the treatment of postoperative vomiting. A double blind comparison between two different dosages (4 mg and 10 mg). , 1979, Acta anaesthesiologica Belgica.